Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of BI 3000202 Pharmacokinetics and Bioavailability in Healthy Participants
NCT07273474Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 3000202 (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Fraction excreted in urine as percentage of the administered dose over the time interval from 0 to the last quantifiable time point up to 21 days, Fraction excreted in faeces as percentage of the administered dose over the time interval from 0 to the last quantifiable time point up to 21 days and 1 more. Started Dec 2025; status: completed.
02
Drugs
BI 3000202
Beyond the preview
Go deeper on NCT07273474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07273474.